Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paula L McClean

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Alzheimer'S & Dementia (Amsterdam, Netherlands)|October 22, 2020
Multi-time-point data preparation robustly reveals MCI and dementia risk factorsDaman Kaur, Magda Bucholc, David P Finn, et al.
Microcirculation (New York, N.Y. : 1994)|January 6, 2015
Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide™Patricia Kelly, Paula L McClean, Maximilian Ackermann, et al.
Journal of Alzheimer'S Disease : JAD|June 21, 2024
Impact of Different Diagnostic Measures on Drug Class Association with Dementia Progression Risk: A Longitudinal Prospective Cohort StudyDaman Preet Kaur, Magda Bucholc, David P Finn, et al.
Pancreas|June 19, 2007
Effects of subchronic treatment with the long-acting glucose-dependent insulinotropic polypeptide receptor agonist, N-AcGIP, on glucose homeostasis in streptozotocin-induced diabetesVictor A Gault, Paula L McClean, Nigel Irwin, et al.
Healthcare Technology Letters|December 14, 2022
Alzheimer's disease classification using cluster-based labelling for graph neural network on heterogeneous dataNiamh McCombe, Jake Bamrah, Jose M Sanchez-Bornot, et al.
American Journal of Physiology. Endocrinology and Metabolism|September 13, 2007
GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat dietPaula L McClean, Nigel Irwin, Roslyn S Cassidy, et al.
Neuropharmacology|May 8, 2020
Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's diseaseAlok Joshi, Da-Hui Wang, Steven Watterson, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|December 3, 2025
Graph-BrainConvNet: A One-class GCN-based approach for MCI detection from source-level MEGKaniska Samanta, Jose Miguel Sanchez-Bornot, Paula L McClean, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|September 10, 2022
Multiple Cost Optimisation for Alzheimer's Disease DiagnosisNiamh McCombe, Xuemei Ding, Girijesh Prasad, et al.
Neuromolecular Medicine|September 27, 2012
The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's diseaseCaitriona M Long-Smith, Sean Manning, Paula L McClean, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Alzheimer'S & Dementia (Amsterdam, Netherlands)|October 22, 2020
Multi-time-point data preparation robustly reveals MCI and dementia risk factorsDaman Kaur, Magda Bucholc, David P Finn, et al.
Microcirculation (New York, N.Y. : 1994)|January 6, 2015
Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide™Patricia Kelly, Paula L McClean, Maximilian Ackermann, et al.
Journal of Alzheimer'S Disease : JAD|June 21, 2024
Impact of Different Diagnostic Measures on Drug Class Association with Dementia Progression Risk: A Longitudinal Prospective Cohort StudyDaman Preet Kaur, Magda Bucholc, David P Finn, et al.
Pancreas|June 19, 2007
Effects of subchronic treatment with the long-acting glucose-dependent insulinotropic polypeptide receptor agonist, N-AcGIP, on glucose homeostasis in streptozotocin-induced diabetesVictor A Gault, Paula L McClean, Nigel Irwin, et al.
Healthcare Technology Letters|December 14, 2022
Alzheimer's disease classification using cluster-based labelling for graph neural network on heterogeneous dataNiamh McCombe, Jake Bamrah, Jose M Sanchez-Bornot, et al.
American Journal of Physiology. Endocrinology and Metabolism|September 13, 2007
GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat dietPaula L McClean, Nigel Irwin, Roslyn S Cassidy, et al.
Neuropharmacology|May 8, 2020
Opportunities for multiscale computational modelling of serotonergic drug effects in Alzheimer's diseaseAlok Joshi, Da-Hui Wang, Steven Watterson, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|December 3, 2025
Graph-BrainConvNet: A One-class GCN-based approach for MCI detection from source-level MEGKaniska Samanta, Jose Miguel Sanchez-Bornot, Paula L McClean, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|September 10, 2022
Multiple Cost Optimisation for Alzheimer's Disease DiagnosisNiamh McCombe, Xuemei Ding, Girijesh Prasad, et al.
Neuromolecular Medicine|September 27, 2012
The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's diseaseCaitriona M Long-Smith, Sean Manning, Paula L McClean, et al.
Pageof 5